Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/update-peripheral-t-cell-lymphomas-30GhcAFXEs
References (61)
-
L. Leval, P. Gaulard (2011)
Pathology and biology of peripheral T‐cell lymphomasHistopathology, 58
-
P. Reimer (2010)
Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell LymphomasAdvances in Hematology, 2010
-
C. Thorns, B. Bastian, D. Pinkel, R. Roydasgupta, J. Fridlyand, H. Merz, M. Krokowski, H. Bernd, A. Feller (2007)
Chromosomal aberrations in angioimmunoblastic T‐cell lymphoma and peripheral T‐cell lymphoma unspecified: A matrix‐based CGH approachGenes, 46
-
A. Forero-Torres, S. Bernstein, A. Gopal, F. Foss, J. Leonard, J. Rosenblatt, N. Bartlett, B. Cheson, E. Epner, Francisco Hernandez-Illizaliturri, S. Proctor, P. Brice, H. Tilly, C. Haioun, M. Jerkeman, A. Bosly, J. Lorenz, J. Barton (2004)
SGN-30 (Anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL)Blood, 106
-
E. Jacobsen, Haesook Kim, V. Ho, C. Cutler, J. Koreth, David Fisher, P. Armand, E. Alyea, A. Freedman, R. Soiffer, J. Antin (2011)
A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome.Annals of oncology : official journal of the European Society for Medical Oncology, 22 7
-
N. Shinton (2007)
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues -
S. Kim, H. Eom, Jin Kim, H. Kang, H. Kim, S. Park, J. Huh, Y. Ko, C. Suh, W. Kim (2010)
The Efficacy of Bortezomib-CHOP In Patients with Advanced Stage T or NK/T Cell Lymphomas: The Results of Multicenter Phase II Study.Blood, 116
-
N. Harris (1994)
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.Blood, 84 5
-
J. Dupuis, J. Emile, N. Mounier, C. Gisselbrecht, N. Martin‐Garcia, T. Petrella, R. Bouabdallah, F. Berger, A. Delmer, B. Coiffier, F. Reyes, P. Gaulard (2006)
Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study.Blood, 108 13
-
K. Savage, M. Chhanabhai, R. Gascoyne, J. Connors (2004)
Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.Annals of oncology : official journal of the European Society for Medical Oncology, 15 10
-
K. Savage, N. Harris, J. Vose, F. Ullrich, E. Jaffe, J. Connors, L. Rimsza, S. Pileri, M. Chhanabhai, R. Gascoyne, J. Armitage, D. Weisenburger (2008)
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.Blood, 111 12
-
O. O’Connor, B. Pro, L. Pinter-Brown, N. Bartlett, L. Popplewell, B. Coiffier, M. Lechowicz, K. Savage, A. Shustov, C. Gisselbrecht, E. Jacobsen, P. Zinzani, R. Furman, A. Goy, C. Haioun, M. Crump, J. Zain, E. Hsi, A. Boyd, S. Horwitz (2011)
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 9
-
R. Fisher, E. Gaynor, S. Dahlberg, M. Oken, T. Grogan, E. Mize, J. Glick, C. Coltman, T. Miller (1993)
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.The New England journal of medicine, 328 14
-
L. Popplewell, Sandra Thomas, Qin Huang, K. Chang, S. Forman (2011)
Primary anaplastic large-cell lymphoma associated with breast implantsLeukemia & Lymphoma, 52
-
Benjamin Kim, C. Roth, V. Young, K. Chung, K. Busum, C. Schnyer, S. Mattke (2011)
Anaplastic Large Cell Lymphoma and Breast Implants: Results from a Structured Expert Consultation ProcessPlastic and Reconstructive Surgery, 128
-
H. Kluin-Nelemans, M. Kooy, P. Lugtenburg, W. Putten, Marleen Luten, J. Oudejans, G. Imhoff (2011)
Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.Annals of oncology : official journal of the European Society for Medical Oncology, 22 7
-
H. O'leary, K. Savage (2009)
Update on the World Health Organization classification of peripheral T-cell lymphomasCurrent Hematologic Malignancy Reports, 4
-
Benoit Ballester, O. Ramuz, C. Gisselbrecht, Gaelle Doucet, L. Loi, B. Loriod, F. Bertucci, R. Bouabdallah, E. Devilard, N. Carbuccia, M. Mozziconacci, D. Birnbaum, P. Brousset, F. Berger, G. Salles, J. Brière, R. Houlgatte, P. Gaulard, L. Xerri (2006)
Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomasOncogene, 25
-
D. Wada, M. Law, E. Hsi, D. DiCaudo, Linglei Ma, M. Lim, A. Souza, N. Comfere, R. Weenig, W. Macon, L. Erickson, Nazan Özsan, S. Ansell, A. Dogan, A. Feldman (2011)
Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsiesModern Pathology, 24
-
I. Bonzheim, E. Geissinger, S. Roth, A. Zettl, A. Marx, A. Rosenwald, H. Müller-hermelink, T. Rüdiger (2004)
Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling.Blood, 104 10
-
A. Zettl, T. Rüdiger, Maria-Anette Konrad, A. Chott, I. Simonitsch-Klupp, R. Sonnen, H. Müller-hermelink, G. Ott (2004)
Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations.The American journal of pathology, 164 5
-
O. Merkel, F. Hamacher, D. Laimer, E. Sifft, Z. Trajanoski, M. Scheideler, G. Egger, M. Hassler, C. Thallinger, Ana-Iris Schmatz, S. Turner, R. Greil, L. Kenner (2010)
Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK− anaplastic large-cell lymphomaProceedings of the National Academy of Sciences, 107
-
I. Salaverria, S. Beà, A. López-Guillermo, V. Lespinet, M. Pinyol, B. Burkhardt, L. Lamant, A. Zettl, D. Horsman, R. Gascoyne, G. Ott, R. Siebert, G. Delsol, E. Campo (2008)
Genomic profiling reveals different genetic aberrations in systemic ALK‐positive and ALK‐negative anaplastic large cell lymphomasBritish Journal of Haematology, 140
-
N. Schmitz, L. Trümper, M. Ziepert, M. Nickelsen, A. Ho, B. Metzner, N. Peter, M. Loeffler, A. Rosenwald, M. Pfreundschuh (2010)
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.Blood, 116 18
-
J. Vose, J. Armitage, D. Weisenburger (2008)
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 25
-
M. Escalón, N. Liu, Ying Yang, M. Hess, P. Walker, T. Smith, N. Dang (2005)
Prognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphomaCancer, 103
-
R. Bast (2011)
Molecular approaches to personalizing management of ovarian cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 22 Suppl 8
-
O. O’Connor, S. Horwitz, P. Hamlin, C. Portlock, C. Moskowitz, D. Sarasohn, E. Neylon, Jill Mastrella, Rachel Hamelers, Barbara Macgregor-Cortelli, Molly Patterson, V. Seshan, F. Sirotnak, M. Fleisher, D. Mould, M. Saunders, A. Zelenetz (2009)
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 26
-
B. Pro, R. Advani, P. Brice, N. Bartlett, J. Rosenblatt, T. Illidge, J. Matous, R. Ramchandren, M. Fanale, J. Connors, Y. Yang, E. Sievers, D. Kennedy, A. Shustov (2011)
Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
A. Feldman, A. Dogan, David Smith, M. Law, S. Ansell, Sarah Johnson, J. Porcher, N. Ozsan, E. Wieben, B. Eckloff, G. Vasmatzis (2011)
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.Blood, 117 3
-
A. Jaccard, N. Gachard, B. Marín, S. Rogez, M. Audrain, F. Suarez, H. Tilly, F. Morschhauser, C. Thieblemont, L. Ysebaert, A. Devidas, B. Petit, L. Leval, P. Gaulard, J. Feuillard, D. Bordessoule, O. Hermine (2011)
Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.Blood, 117 6
-
T. Relander, G. Lauritzsen, E. Jantunen, H. Hagberg, H. Anderson, E. Cavallin-ståhl, H. Holte, A. Österborg, M. Merup, P. Brown, B. Østenstad, O. Kuittinen, M. Erlanson, U. Fagerli, O. Gadeberg, C. Sundström, J. Delabie, E. Ralfkiaer, M. Vornanen, F. d'Amore (2010)
Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)Blood, 116
-
F. Foss, N. Sjak-Shie, A. Goy, R. Advani, E. Jacobsen (2010)
Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial.Journal of Clinical Oncology, 28
-
R. Gascoyne, P. Aoun, Daniel Wu, M. Chhanabhai, B. Skinnider, T. Greiner, S. Morris, J. Connors, J. Vose, D. Viswanatha, A. Coldman, D. Weisenburger (1999)
Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma.Blood, 93 11
-
S. Morris, M. Kirstein, M. Valentine, K. Dittmer, D. Shapiro, D. Saltman, A. Look (1994)
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.Science, 267 5196
-
R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, T. Yoshino, H. Yamabe, M. Shiota, S. Mori, M. Ogura, N. Hamajima, M. Seto, T. Suchi, Y. Morishima, S. Nakamura (2000)
Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype.Blood, 96 9
-
A. Delmer, O. Fitoussi, P. Gaulard, G. Laurent, D. Bordessoule, F. Morschhauser, C. Fermé, H. Tilly, C. Gisselbrecht, B. Coiffier (2016)
A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1T trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
Stina Enqvist, U. Mellqvist, J. Mölne, K. Sletten, C. Murphy, A. Solomon, F. Stevens, P. Westermark (2009)
A father and his son with systemic AL amyloidosisHaematologica, 94
-
L. Dehner (1991)
Ki-1 lymphoma.Pediatric pathology, 11 1
-
A. Evens, L. Gordon, D. Patton, S. Rosen, J. Winter, J. Kline, K. Besien, Sonali Smith (2008)
Phase I Results of Combination Gemcitabine and Bortezomib (Velcade®) for Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL).Blood, 112
-
R. Berge, P. Bruin, J. Oudejans, G. Ossenkoppele, P. Valk, C. Meijer (2003)
ALK‐negative anaplastic large‐cell lymphoma demonstrates similar poor prognosis to peripheral T‐cell lymphoma, unspecifiedHistopathology, 43
-
D. Lazzeri, T. Agostini, G. Bocci, Giordano Giannotti, G. Fanelli, A. Naccarato, R. Danesi, M. Tuccori, M. Pantaloni, C. D'aniello (2011)
ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity.Clinical breast cancer, 11 5
-
S. Gouill, N. Milpied, A. Buzyn, R. Latour, J. Vernant, M. Mohty, M. Moles, K. Bouabdallah, C. Bulabois, J. Dupuis, B. Rio, N. Gratecos, I. Yakoub-Agha, M. Attal, O. Tournilhac, D. Decaudin, J. Bourhis, D. Blaise, C. Volteau, M. Michallet (2008)
Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 14
-
G. Corazzelli, F. Frigeri, G. Marcacci, C. Becchimanzi, G. Capobianco, M. Arcamone, E. Morelli, F. Volzone, F. Russo, A. Pinto (2010)
Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.Blood, 116
-
O. O’Connor (2010)
Novel agents in development for peripheral T-cell lymphoma.Seminars in hematology, 47 Suppl 1
-
G. Dueck, N. Chua, A. Prasad, D. Finch, D. Stewart, D. White, R. Jagt, J. Johnston, A. Belch, T. Reiman (2010)
Interim report of a phase 2 clinical trial of lenalidomide for T‐cell non‐Hodgkin lymphomaCancer, 116
-
L. Leval, D. Rickman, C. Thielen, A. Reyniès, Yenlin Huang, G. Delsol, L. Lamant, K. Leroy, J. Brière, T. Molina, F. Berger, C. Gisselbrecht, L. Xerri, P. Gaulard (2007)
The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.Blood, 109 11
-
B. Pohlman, R. Advani, M. Duvic, K. Hymes, T. Intragumtornchai, A. Lekhakula, O. Shpilberg, A. Lerner, D. Ben-yehuda, M. Beylot‐Barry, U. Hillen, J. Fagerberg, F. Foss (2009)
Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma.Blood, 114
-
Liuyan Jiang, C. Yuan, Julia Hubacheck, J. Janik, W. Wilson, J. Morris, G. Jasper, M. Stetler-Stevenson (2009)
Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapyBritish Journal of Haematology, 145
-
D. Weisenburger, K. Savage, Nancy Harris, R. Gascoyne, Elaine Jaffe, Kenneth Maclennan, Thomas Rüdiger, Stefano Pileri, Shigeo Nakamura, Bharat Nathwani, Elías Campo, Françoise Berger, B. Coiffier, Won-Seog Kim, H. Holte, Massimo Federico, W. Au, K. Tobinai, James Armitage, J. Vose (2011)
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.Blood, 117 12
-
R. Piekarz, R. Frye, H. Prince, M. Kirschbaum, J. Zain, S. Allen, E. Jaffe, A. Ling, M. Turner, C. Peer, W. Figg, S. Steinberg, Sonali Smith, D. Joske, I. Lewis, L. Hutchins, M. Craig, A. Fojo, J. Wright, S. Bates (2011)
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.Blood, 117 22
-
P. Zinzani, C. Pellegrini, A. Broccoli, V. Stefoni, L. Gandolfi, F. Quirini, L. Argnani, E. Berti, E. Derenzini, S. Pileri, M. Baccarani (2011)
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specifiedLeukemia & Lymphoma, 52
-
B. Coiffier, B. Pro, H. Prince, F. Foss, L. Sokol, M. Greenwood, D. Caballero, P. Borchmann, F. Morschhauser, M. Wilhelm, L. Pinter-Brown, S. Padmanabhan, A. Shustov, J. Nichols, S. Carroll, J. Balser, S. Horwitz (2010)
Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic TherapyBlood, 116
-
L. Lamant, A. Reyniès, M. Duplantier, D. Rickman, F. Sabourdy, S. Giuriato, L. Brugières, P. Gaulard, E. Espinos, G. Delsol (2007)
Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes.Blood, 109 5
-
A. Simon, M. Péoch, P. Casassus, E. Deconinck, P. Colombat, B. Desablens, O. Tournilhac, H. Eghbali, C. Foussard, J. Jaubert, J. Vilque, J. Rossi, V. Lucas, V. Delwail, A. Thyss, F. Maloisel, N. Milpied, S. Gouill, T. Lamy, R. Gressin (2010)
Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95British Journal of Haematology, 151
-
N. Mourad, N. Mounier, J. Brière, E. Raffoux, A. Delmer, A. Feller, C. Meijer, Jean-François Emile, R. Bouabdallah, A. Bosly, J. Diebold, C. Haioun, B. Coiffier, C. Gisselbrecht, P. Gaulard (2008)
Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.Blood, 111 9
-
Jong Kim, S. Sohn, Y. Chae, Y. Cho, Deok-Hwan Yang, Je-Jung Lee, Hyeoung-Joon Kim, Ho-Jin Shin, J. Chung, G. Cho, W. Lee, Y. Joo, C. Sohn, Sukjoong Oh (2007)
Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II studyCancer Chemotherapy and Pharmacology, 60
-
J. Iqbal, D. Weisenburger, T. Greiner, J. Vose, T. Mckeithan, C. Kűcűk, H. Geng, Karen Deffenbacher, Lynette Smith, K. Dybkaer, S. Nakamura, M. Seto, J. Delabie, F. Berger, F. Loong, W. Au, Y. Ko, I. Sng, J. Armitage, W. Chan (2010)
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.Blood, 115 5
-
C. Bastard, R. Rimokh, N. Dastugue, J. Huret, U. Kristoffersson, J. Magaud, C. Nezelof, H. Tilly, J. Vannier, J. Hemet, R. Warnke (1990)
CD30‐positive large cell lymphomas (‘Ki‐1 lymphoma’) are associated with a chromosomal translocation involving 5q35British Journal of Haematology, 74
-
A. Gallamini, C. Stelitano, R. Calvi, M. Bellei, D. Mattei, U. Vitolo, F. Morabito, M. Martelli, E. Brusamolino, E. Iannitto, F. Zaja, S. Cortelazzo, L. Rigacci, L. Devizzi, G. Todeschini, G. Santini, M. Brugiatelli, M. Federico (2004)
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.Blood, 103 7
-
D. Sibon, M. Fournier, J. Brière, L. Lamant, C. Haioun, B. Coiffier, S. Bologna, P. Morel, J. Gabarre, O. Hermine, A. Sonet, C. Gisselbrecht, G. Delsol, P. Gaulard, H. Tilly (2010)
Prognostic Factors and Long Term Outcome of 138 Adults with Systemic Anaplastic Large-Cell Lymphoma: a Retrospective Study by the Groupe d'Etude Des Lymphomes De l'Adulte (GELA)Blood, 116
- Publisher
- Springer Journals
- Copyright
- Copyright © 2011 by Springer Science+Business Media, LLC
- Subject
- Medicine & Public Health; Geriatrics/Gerontology; Oncology; Hematology
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- DOI
- 10.1007/s11899-011-0100-3
- pmid
- 21953415
- Publisher site
- See Article on Publisher Site
Abstract
Peripheral T-cell lymphomas (PTCLs) are a group of biologically heterogeneous but typically aggressive diseases. Progress in understanding and developing optimal therapies for PTCLs has been hampered by disease rarity and only relatively recent recognition of the importance of the T-cell phenotype. The International Peripheral T-cell Lymphoma Project was a large collaborative effort to provide a broader understanding of prognosis. Recently, several new therapies have shown promise in the treatment of PTCLs.
Journal
Current Hematologic Malignancy Reports – Springer Journals
Published: Sep 28, 2011